تفاعل #328402

ord-fda1821d67f44c5dab588b4535bfd492

ظروف التفاعل

الظروف التفصيلية
See reaction.notes.procedure_details.

المعالجة

  1. 1
    أخرىPrepared

الإجراء التجريبي

Prepared according to the method of example 25 by using N-ethyl-5-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-benzimidazol-2-amine dihydrochloride (example 11, step 3) and 2,4-dichloroquinazoline in step 1 and ethylamine in step 2. 1H NMR (400 MHz, DMSO-d6) δ 7.80 (d, 1H), 7.57-7.48 (m, 2H), 7.43 (s, 1H), 7.36-7.28 (m, 2H), 7.19-7.11 (m, 2H), 7.07-6.95 (m, 2H), 6.72-6.58 (m, 1H), 4.95 (s, 2H), 4.43 (s, 2H), 4.11 (s, 2H), 3.32-3.25 (m, 4H), 1.91 (d, 4H), 1.18 (t, 6H); MS (EI) for C28H29N7O: 480 (MH+).

المصدر

DOI: 10.6084/m9.figshare.5104873.v1براءة الاختراع: US08648066B2uspto-grants-2014_02